Adma Biologics, Inc. SEC filings ADMA
Adma Biologics, Inc. has 999 filings in SEC EDGAR's recent list, going back to Jul 10, 2006. Its latest annual report, Form ARS, was filed on Apr 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 15, 2026 | — |
| DEF 14A | Proxy statement | Apr 15, 2026 | Jun 2, 2026 |
| DEFA14A | Additional proxy material | Apr 15, 2025 | — |
| DEF 14A | Proxy statement | Apr 15, 2025 | Jun 4, 2025 |
| DEFA14A | Additional proxy material | Apr 15, 2024 | — |
| DEF 14A | Proxy statement | Apr 15, 2024 | Jun 4, 2024 |
| DEFA14A | Additional proxy material | May 22, 2023 | — |
| DEFA14A | Additional proxy material | Apr 13, 2023 | — |
| DEF 14A | Proxy statement | Apr 13, 2023 | Jun 6, 2023 |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 21, 2022 |
| DEFA14A | Additional proxy material | Apr 8, 2021 | — |
| DEF 14A | Proxy statement | Apr 7, 2021 | May 27, 2021 |
| PRE 14A | Preliminary proxy statement | Mar 26, 2021 | Mar 26, 2021 |
| DEFA14A | Additional proxy material | Apr 29, 2020 | — |
| DEF 14A | Proxy statement | Apr 29, 2020 | Jun 18, 2020 |
| DEF 14A | Proxy statement | Jul 16, 2019 | Aug 23, 2019 |
| PRE 14A | Preliminary proxy statement | Jul 1, 2019 | Aug 23, 2019 |
| DEF 14A | Proxy statement | Apr 24, 2019 | Jun 5, 2019 |
| PRE 14A | Preliminary proxy statement | Apr 5, 2019 | Jun 5, 2019 |
| DEFA14A | Additional proxy material | Jun 4, 2018 | — |
| DEF 14A | Proxy statement | Apr 27, 2018 | Jun 22, 2018 |
| DEFA14A | Additional proxy material | May 10, 2017 | — |
| DEFM14A | Filing | Apr 26, 2017 | — |
| PREM14A | Filing | Mar 15, 2017 | Mar 15, 2017 |
| DEF 14A | Proxy statement | Apr 29, 2016 | Jun 7, 2016 |
| DEF 14A | Proxy statement | Apr 30, 2015 | Jun 23, 2015 |
| DEF 14A | Proxy statement | Apr 29, 2014 | Jun 19, 2014 |
| DEF 14A | Proxy statement | Jul 25, 2013 | Aug 8, 2013 |
| PRE 14A | Preliminary proxy statement | Jul 2, 2013 | Jun 27, 2013 |
| DEF 14C | Information statement | Oct 29, 2012 | Oct 29, 2012 |
Showing 31 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ADMA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Ramsey, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1368514
- Former names
- R&R ACQUISITION VI, INC (until Feb 21, 2012)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.